Cardiometabolic Health Screening Trial Access Partner

Care Access
FUTURE OF MEDICINE

Provide your patients with access to free testing, education, and clinical research opportunities

Promising breakthrough treatments for cardiovascular disease are on the horizon. Access to these new and emerging treatments is often limited to patients connected to research institutes or academic medical centers involved in clinical trials.

Care Access is a leading global research network with a mission to increase access to clinical trials for patients and communities typically left out of the process. Partner with us to create access to leading-edge clinical trials and health screening opportunities for your patients.

Join the Future of Medicine.

Future of Medicine Program

Help your patients uncover potential health risks and learn about clinical research opportunities that could benefit them, their families, their communities, and the world.

Free Cardiometabolic Screening

Patients get a free blood test for 3 major health risks (Lp(a), diabetes, kidney disease)

Health Information

Patients have access to the latest medical information (relevant articles, videos, current research findings) to help them on their health journey



Clinical Trial Opportunities

Patients learn about new clinical trial opportunities based on their health profiles

No-cost Cardiometabolic Health Screening

The medical community is embracing a broader look at heart health that focuses on the shared risks that lead to heart disease as well metabolic and kidney disease. Our no-cost cardiometabolic health screening covers a number of tests, including an Lp(a), which most patients do not currently have access to. In addition to Lp(a), we'll test for other risk factors of cardiometabolic disease such as hemoglobic A1C and eGFR.

Importance of Lp(a) Screening for Your Patients

When assessing lipids, LDL, HDL, and triglycerides take center stage. However, another significant contributor—lipoprotein(a), or Lp(a), has shown to silently block arteries and induce inflammation. Elevated Lp(a) significantly increases the risk of cardiovascular disease, including having a 50% increased risk for a heart attack compared to people with lower Lp(a).[1]



Elevated Lp(a) At-a-Glance

Prevalence	Most common genetic dyslipidemia globally, impacting at least 1 in 5 individuals.
Causes	Genetically determined and stable by age 5; not significantly impacted by lifestyle or medications.[2]
Risks	Lp(a) is associated with a higher risk of heart attack and aortic stenosis. Individuals with Lp(a) levels >30 mg/dL face a high cardiovascular risk, with 1 in 3 individuals falling into this category.[3]
Clinical Limitations	Lack of targeted therapies has led to limited insurance coverage for testing, which in turn led to a lack of awareness for patients and physicians.
Practice-Changing Breakthroughs on the Horizon	Next-generation therapies that use RNA silencing technology to significantly reduce Lp(a) are currently being evaluated in clinical trials.[4] These therapies are injections every 1–2 months and may be able to reduce Lp(a) levels by >90%.



1 in 14 heart attacks and

1 in 7 cases of aortic valve disease

are due to Lipoprotein(a) cholesterol[5]

---

1 Patel A.P., Wang (汪敏先) M., Pirruccello J.P., Ellinor P.T., Ng K., Kathiresan S., Khera A.V., *Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank.* Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):465-474. doi: 10.1161/ATVBAHA.120.315291. Epub 2020 Oct 29. PMID: 33115266; PMCID: PMC7769893.

2 Reyes-Soffer G., Ginsberg H.N., Berglund L., Duell P.B., Heffron S.P., Kamstrup P.R., Lloyd-Jones D.M., Marcovina S.M., Yeang C., Koschinsky M.L., *Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association.* Arterioscler. Thromb. Vasc. Biol. 2022;42:48–60. doi: 10.1161/ATV.0000000000000147

3 Rikhi R., Hammoud A., Ashburn N., Snavely A.C., Michos E.D., Chevli P., Tsai M.Y., Herrington D., Shapiro M.D., *Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis*. 2022;363:102–108. doi: 10.1016 jatherosclerosis.2022.10.004.

4 Sosnowska B., Surma S., Banach M., *Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy.* Pharmaceuticals (Basel). 2022 Dec 16;15(12):1573. doi: 10.3390/ph15121573. PMID: 36559024; PMCID: PMC9781646.

5 Afshar M., Kamstrup P.R., Williams K., Sniderman A.D., Nordestgaard B.G., Thanassoulis G., *Estimating the population impact of Lp(a) lowering on the incidence of myocardial infarction and aortic stenosis-brief report*. Arterioscler Thromb Vasc Biol 2016; 36: 2421–2423.

Screening and Clinical Trials—Offered by You

Community physicians are key to making clinical trials accessible to all patients. By partnering with Care Access as a Trial Access Partner on the Future of Medicine program, you can help your patients get screened for cardiometabolic health risks and access new investigational treatments through your practice.

Supporting Your Patients as a Trial Access Partner

We partner with community-based practices and healthcare centers in urban, suburban, and rural settings to bring screening and clinical trials into their communities. **Here's how we work with our Trial Access Partners:**

	Trial Access Partner	Care Access
 **Learn**	You provide patients with information about screening (in-office, EMR messages, phone calls, etc.)	We provide your practice with educational materials and staff support to help spread the word
 **Schedule**	You provide patients with a practice-specific online scheduling link	We handle online scheduling and screening communications
 **Lab Test**		We manage patient screening blood draws at, or near, your office
 **Results**	You receive patients' test results (if they consent) and continue to guide their regular care	We communicate results directly back to patients
 **Educate**		We engage participants with health and clinical research information
 **Match**	You help educate your patients on new trial opportunities.	We let participants know if they potentially qualify for a clinical trial. We keep you informed about your patients who are enrolled in a trial

Why Become a Partner of the Future of Medicine Program?

- Provide access to a resource for your patients: no-cost health screening (plus, they receive a stipend for participating)
- Drive cardiometabolic health awareness (including lesser-known Lp(a) risks) and create an opportunity to initiate needed interventions with your patients
- Facilitate patient access to clinical trials for emerging treatments for Lp(a) and other cardiometabolic health risks
- Play an important role in shaping the future of medicine
- Generate supplemental revenue for your practice

Join the Future of Medicine program as a Trial Access Partner

Email: **Trial.Access.Partners@careaccess.com**

Visit: **start.careaccess.com/cardiometabolic**

Cardiovascular Advisory Board

The Care Access Cardiovascular Advisory Board provides expert opinion on important issues impacting clinical trials, including patient safety, quality, and creating access for communities that are underrepresented in clinical research. They also provide oversight and guidance for the cardiometabolic health screenings and educational resources provided to those participating in the Future of Medicine program by Care Access.

Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Johns Hopkins Medicine

Dr. Michos is an internationally-recognized expert on women's cardiovascular health, lipids, and cardiometabolic diseases. She is a co-investigator in the NIH-funded Multi-Ethnic Study of Atherosclerosis (MESA) and Atherosclerosis Risk in Communities (ARIC) studies, and Training Director for three American Heart Association Strategic Focused Research Networks (SFRN) in Women's Cardiovascular Health, Cardiometabolic Disease, and Health Technology. Additionally, Dr. Michos holds the position of Co-Editor in Chief for the American Journal of Preventive Cardiology.

As the Director of Women's Cardiovascular Health Research at Johns Hopkins, she educates women around the world about cardiometabolic disease risk factors. Her work also focuses on building strong relationships in communities to increase diversity and representation in clinical research through the IMPACT Center at Johns Hopkins, which she co-directs.

Irving Loh, MD, FACC, FACP, FAHA, FCCP

Ventura Heart Institute

Dr. Loh is a cardiologist with long-established expertise in cardiometabolic clinical trial design and execution. Dr. Loh has served as a Principal Investigator on over 160 clinical trials focused on cardiovascular health during his time at the National Institutes of Health, Cedars-Sinai Medical Center, and the Ventura Heart Institute, which he founded. These included trials for all the statins, PCSK9 inhibitor monoclonal antibodies, CETP inhibitors, and nonstatin investigational products. Dr. Loh also served as the Chair of the Institutional Review Board for his regional hospital for 18 years and as an advisor to many health technology organizations and industry sponsors.

Seth Shay Martin, MD, MHS, FACC, FAHA, FASPC

Johns Hopkins Medicine

Dr. Martin is a cardiologist and world-leading expert in the science of lipids. The Martin/Hopkins method, the most accurate way to calculate LDL cholesterol levels, was created by and named after him and his team at Johns Hopkins, and is now used around the world. As a committed advocate for equity in healthcare and as the Director of the Advanced Lipid Disorders Program and Director of the Center for Mobile Technologies to Achieve Equity in Cardiovascular Health (mTECH) at Johns Hopkins Medicine. He is deeply involved in research projects that shed light on ethnic differences in cardiovascular health, inclusive health technology to bridge the digital divide, and addressing barriers to care in predominantly Black communities of Maryland. He also mentors early-stage investigators helping to build a diverse research workforce.

Ankur Kalra, MD, FACP, FACC, FSCAI

Franciscan Health

Dr. Kalra is an interventional cardiologist with vast experience in clinical research, including through his previous role as Medical Director of Clinical Research for Cleveland Clinic's regional community-based hospitals. He is widely known for applying his scientific expertise towards helping South Asian and rural communities that are disproportionately impacted by heart disease. His lifelong work to address heart health disparities among South Asians, who have 4x the risk of cardiovascular disease, has helped build international awareness and collaboration among healthcare professionals.

About Care Access

Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.